O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (1) , 28-32
- https://doi.org/10.1215/s115285170300019x
Abstract
The purpose of the study was to determine the dose of O6-benzylguanine (BG) that would suppress O6-alkylguanine-DNA alkyltransferase (AGT) activity tKeywords
This publication has 17 references indexed in Scilit:
- Multifaceted resistance of gliomas to temozolomide.2002
- Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 2002
- Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.2001
- Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.2001
- O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.1999
- O6-benzylguanine and its role in chemotherapy.1997
- Human liver oxidative metabolism of O6-benzylguanineBiochemical Pharmacology, 1995
- Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cellsBritish Journal of Cancer, 1993
- Treatment of subcutaneous and intracranial brain tumor xenografts withO 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosoureaCancer Chemotherapy and Pharmacology, 1993
- O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenograftsJournal of Neurosurgery, 1989